Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
The Japanese Association for Infectious Diseases, the Japanese Respiratory Society, and the Japanese Society for Vaccinology issued a joint statement on October 17 saying that they strongly recommend taking COVID-19 shots under the national immunization program (NIP). The statement emphasized…
To read the full story
Related Article
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- Refusal to See Patients due to Kostaive Shots Might Violate “Duty of Care”: Lawyer
December 17, 2024
- Meiji Seika Pharma “Preparing” to Sue CDP’s Haraguchi
November 5, 2024
- Ex-Health Minister Gets Kostaive Shot, Warns against “Unscientific Concerns”
October 21, 2024
- Meiji Rebuts Nursing Group’s Claim on Concerns over Kostaive
October 10, 2024
- Negative Impact of Rumors on Kostaive Is Immense: Meiji Pharma President
October 9, 2024
- Meiji’s COVID Jab Might Miss Initial Plan, but Awaits Real Game Next Year
September 26, 2024
ACADEMIA
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…